InvestInMJ Admin

BEVERLY HILLS, CA--(Marketwired - May 26, 2015) -  mCig, Inc. (OTCQB: MCIG), a leading provider of technology, products, and services for consumers, dispensaries, and growers within the global medical and recreational marijuana industry, announced on Tuesday, May 26, 2015 the plan to open a Southern Colorado Cultivation and Extraction Facility. The Extraction Division will oversee the operation of the facility, cultivating and extracting a world-class product for legal consumers in Colorado, allowing mCig to create another stable revenue stream in the cannabis extraction industry, which some analysts predict will reach $47B in revenue in 2016. The blueprint for this pilot facility will also be easily duplicated in other locations. In addition to the plan, mCig announced the completion of an agreement with Denver-based Master Grower and Cannabis Entrepreneur Derek DeCosmo to serve as a Key Partner and consultant for the upcoming Cultivation Facility. Mr. DeCosmo will also be responsible for providing logistical support for the Extraction portion of the Facility. 

Mr. DeCosmo has over a decade of professional growing experience as well as an extensive network of farmers and dispensaries across the state from which to pool resources. Mr. DeCosmo has worked with Personal Organic Therapies in Denver in the past, and is extremely excited to be involved with the mCig Southern Colorado Operation. Mr. DeCosmo commented, "When Mike Snody (mCig's Chief Research and Development Officer) laid out the master plan and invited me to join this operation, I was immediately on board. I am putting 100 percent of my energy into ensuring the success of the Southern Colorado Operation. I grow the most potent, highest quality strains, and I'm constantly pushing the envelope, and I look forward to putting that knowledge and experience to work for mCig in Colorado. I have access to the absolute best, award-winning cuts and world-renowned strains in the world which we will use to create the finest concentrates available on the planet." The Southern Colorado facility will allow the Extraction Division to field test the upcoming Supercritical Co2 Extractor. 

RENO, NV--(Marketwired - May 27, 2015) - INTERACTIVE HEALTH NETWORK (OTC PINK: IGRW), a health company specializing in advances in Supplements for Health and Anti-Aging today announces the formation of three new divisions for focus and execution under the guidance of their recently announced CEO Cesar Vazquez:

• Indoor Garden/Hydroponics Division
• Cannabis Oil Nutraceutical Products Division
• CBD Sports Nutrition Energy Drinks Division

The Indoor Garden/Hydroponics Division will focus on marketing and selling a line of private labeled proprietary products including, but not limited to, light hoods, ballasts, grow bulbs, fans and nutrients. "We plan on launching a very cost effective line of product that leverages my years of real world experience in world class hydroponic products marketed and sold in both our physical retail location and online ecommerce. This market is explosive in growth and in a known need for high quality, but cost effective equipment and optimized nutrients" stated Cesar Vazquez, CEO of Interactive Health Network.

The Cannabis Oil Nutraceutical Products Division will design, produce, market and sell Non THC CBD Capsules and Tinctures, Non THC Oil Capsules and Hemp Oil Topical Creams. "The natural medicinal benefits of CBD and Hemp Oil can benefit many people as an organic option to chemically manufactured alternatives" stated Cesar Vazquez, CEO of Interactive Health Network.

The Drug Enforcement Administration (DEA) is proposing to adjust the established 2015 aggregate production quota for marijuana.  While marijuana is a scheduled I drug and the laws around it are enforced by the DEA, they do allow several government agencies and registered manufacturers to produce it for research and product development.

Registered manufacturers and the National Institute on Drug Abuse (NIDA) have requested a higher quota for production and supply of marijuana for 2015.  The previous 2015 established quote for marijuana was 125,000 g, and the new adjusted quota for 2015 is 400,000 g.

Highlights from the Federal Register Notice:

Background:

The DEA established the initial 2015 aggregate production quotas and assessments of annual need on September 8, 2014 (79 FR 53216). That notice stipulated that, as provided for in 21 CFR 1303.13, all aggregate production quotas and assessments of annual need are subject to adjustment.

Based on unanticipated medical, scientific, research, and industrial needs of the United States the DEA proposes to adjust the established 2015 aggregate production quotas for the schedule I and II controlled substances difenoxin, diphenoxylate (for conversion), and marijuana to be manufactured in the United States in 2015. The adjustment is necessary to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks.

In proposing the adjustment, the Administrator has taken into account the following criteria in accordance with 21 CFR 1303.13: (1) Changes in demand for the basic class, changes in the national rate of net disposal for the class, and changes in the rate of net disposal by the registrants holding individual manufacturing quotas for the class; (2) whether any increased demand or changes in the national and/or individual rates of net disposal are temporary, short term, or long term; (3) whether any increased demand for that class can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota; (4) whether any decreased demand will result in excessive inventory accumulation by all persons registered to handle the class; and (5) other factors affecting the medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Administrator finds relevant.

Analysis for Adjusting the Established 2015 Aggregate Production Quota for Marijuana:

Since the establishment of the initial 2015 aggregate production quotas, the DEA has received notification from DEA registered manufacturers that research and product development involving cannabidiol, is increasing beyond that previously anticipated for 2015. The associated product development activities are related to process validation and commercialization activities, including qualification activities related to potential U.S. Food and Drug Administration submission support.

Additionally, the DEA has also received notification from the National Institute on Drug Abuse (NIDA) that it required additional supplies of marijuana to be manufactured in 2015 to provide for ongoing and anticipated research efforts involving marijuana. NIDA is a component of the National Institutes of Health and the U.S. Department of Health and Human Services which oversees the cultivation, production and distribution of research-grade marijuana on behalf of the United States Government, pursuant to the Single Convention on Narcotic Drugs (March 30, 1961, 18 UST 1407).

The Administrator Michele M. Leonhart, therefore, proposes to adjust the 2015 aggregate production quotas for difenoxin, diphenoxylate (for conversion), and marijuana, expressed in grams of anhydrous acid or base.

You can read the full Notice by the DEA and provide your opinion as they are requesting comments.

Sign up for our newsletter to get the latest marijuana industry news and opportunities sent to you directly.

{loadposition imjnews}